3 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2022-08-05 | |
| Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients Abiraterone, Apalutamide - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Withdrawn | University of Athens | 2018-01-01 | 2020-11-18 | |
| A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer JNJ-809, Apalutamide - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Withdrawn | Janssen Research & Development, LLC | 2016-10-01 | 2016-11-22 |
Genital Diseases (3) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Male Urogenital Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Prostatic Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Prostatic Neoplasms (1)
apalutamide (2) · Abiraterone Acetate (1) · abiraterone (1) · enzalutamide (1)
Janssen Research & Development, LLC (1) · Nuvation Bio Inc. (1) · University of Athens (1)
United States (2)
2016 (1), 2017 (1)